Saluda Medical today announced the full launch of its EVA next-generation sensing technology for its neuromodulation therapy.
Minneapolis-based Saluda develops the Evoke neuromodulation system. The spinal cord stimulation (SCS) platform treats chronic pain. Saluda raised $100 million to support the technology earlier this year and appointed a new CEO this month.
EVA won FDA approval in December 2024 and works for all commercially implanted Saluda Evoke SmartLoop system patients. The Evoke extension objectively scans and analyzes a patient’s spinal cord to deliver personalized therapy with precision. It optimizes patient outcomes by sensing, measuring and adjusting stimulation based on each patient’s neural response biomarker. This maintains therapy at the patient’s prescribed level.
Related: CorWave’s undulating membrane heart pump implanted in first patient
“This full commercial launch represents a significant advancement in SCS therapy and delivers on the promise of objective dosing and more effective pain relief for patients,” said Mike Mathias, Chief Commercial Officer at Saluda Medical. “In addition to its clinical benefits, EVA automates manual programming steps, thereby improving the patient experience.”
Since receiving FDA approval, Saluda reports more than 3,000 commercial utilizations of EVA through a limited rollout.
“The Evoke SmartLoop System with EVA provides objective dosing that enables more predictable and durable outcomes in SCS,” said Dr. Jason Pope, founder and CEO, Evolve Restorative Center. “The data premiering at ASPN 2025 further demonstrates the compelling clinical benefits of the Evoke SmartLoop System, including increasing the diagnostic value of the trial phase and maintaining therapy response over time without loss of efficacy.”
